Get started
Author

Боденко Виталина Васильевна

Observed names: V. V. Bodenko, Vitalina Bodenko, Боденко, В. В., Боденко, Виталина Васильевна, В. В. Боденко
Observed institutions: Uppsala University, Russian Academy of Sciences, Siberian State Medical University, Tomsk Polytechnic University, Ministry of Health of the Russian Federation, Tomsk National Research Medical Center
ORCID: 0000-0001-5097-9737
Observed ORCID: 0000-0001-5097-9737
OpenAlex ID: A5019699725
Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
2023 · Yongsheng Liu, Tianqi Xu, et al. · Cancers · 25
PDF
Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs
2023 · Wen Yin, Tianqi Xu, et al. · Journal of Controlled Release · 19
Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
2024 · Jie Zhang, Vitalina Bodenko, et al. · Journal of Controlled Release · 16
PDF
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu
2024 · Aleksei E. Machulkin, Stanislav A. Petrov, et al. · ACS Pharmacology & Translational Science · 16
PDF
Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile
2024 · Yongsheng Liu, Maryam Oroujeni, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 14
PDF
Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
2022 · Yongsheng Liu, Shengze Yu, et al. · Pharmaceutics · 14
PDF
Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
2022 · Vladimir Tolmachev, Vitalina Bodenko, et al. · International Journal of Molecular Sciences · 12
Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
2022 · Tianqi Xu, Jie Zhang, et al. · Pharmaceutics · 10
PDF
177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
2023 · Ayman Abouzayed, Kamila Seitova, et al. · Frontiers in Oncology · 8
PDF
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures
2023 · Lutfi A. Hasnowo, Maria S. Larkina, et al. · International Journal of Molecular Sciences · 7
PDF
Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
2022 · Yongsheng Liu, Rezan Güler, et al. · Pharmaceutics · 7
PDF
Visualization of epithelial cell adhesion molecule‑expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with 99mTc and 125I
2022 · Vladimir Tolmachev, Vitalina Bodenko, et al. · Oncology Letters · 7
PDF
Novel Chlorin with a HYNIC: Synthesis, 99mTc-Radiolabeling, and Initial Preclinical Evaluation
2024 · Alexander Popov, Nikita Suvorov, et al. · Molecules · 5
PDF
Molecular targets for metastasis-directed therapy in malignant tumors
2024 · V. V. Bodenko, M. S. Larkina, et al. · Bulletin of Siberian Medicine · 5
PDF
The Use of Glycine-Containing Peptide-Based Chelators for Labeling with 99m Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1
2026 · Sergey Deyev, Anastasia Fominykh, et al. · Molecular Pharmaceutics · 4
Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr
2025 · Stanislav A. Petrov, Gleb P. Grigoriev, et al. · Bioconjugate Chemistry · 4
PDF
The position of 99mTc-HYNIC and the molecular design of the DARPin G3 constructs influence the selection of an imaging tracer to detect expression in HER2-expressing tumors
2026 · Maria Larkina, Ruslan Varvashenya, et al. · Journal of Radioanalytical and Nuclear Chemistry · 2
Validation of an Analytical HPLC Method for a New Diagnostic Octreotide Derivative for Neuroendocrine Tumors
2019 · M. S. Lar’kina, S. V. Krivoshchekov, et al. · Pharmaceutical Chemistry Journal · 1
Targeted Radionuclide Therapy and Diagnostics of EGFR-Expressing Tumors: Current State and Future Perspectives (Review)
2026 · G. E. Yanovich, V. V. Bodenko, et al. · Ведомости Научного центра экспертизы средств медицинского применения
PDF
Evaluation of the Functional Suitability of Carboxylate Chlorin e6 Derivatives for Use in Radionuclide Diagnostics
2025 · Mariia Larkina, Anastasia Demina, et al. · Pharmaceutics
PDF
Strategy for the development of targeted agents for therapy of HER2-positive breast cancer
2025 · V. V. Bodenko, M. S. Larkina, et al. · Siberian Journal of Oncology
PDF
Валидация ВЭЖХ методики анализа нового производного октреотида для диагностики нейроэндокринных опухолей
2019 · Мария Сергеевна Ларькина, С. В. Кривощеков, et al. · Химико-фармацевтический журнал
Стратегия Разработки Таргетных Препаратов Для Терапии Her2-позитивного Рака Молочной Железы
· Боденко Виталина Васильевна, Ларькина Мария Сергеевна, et al. · CyberLeninK (CyberLeninka)
Works count: 29
Citation count: 176
H-index: 8
I10-index: 8
Year
Topic
Type